Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer - Wikidata - wikimedia - TriplyDB

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer

http://www.wikidata.org/entity/Q28290629

about

Novel drugs that target the metabolic reprogramming in renal cell cancer Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect Dysregulated metabolism contributes to oncogenesis Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication Review of aerobic glycolysis and its key enzymes - new targets for lung cancer therapy Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.Novel therapeutic targets of tumor metabolism Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells Heterogeneity of glycolysis in cancers and therapeutic opportunities.ROS homeostasis and metabolism: a critical liaison for cancer therapy Adipose tissue dysfunction and its effects on tumor metabolism Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27 Kinome Screen Identifies PFKFB3 and Glucose Metabolism as Important Regulators of the Insulin/Insulin-like Growth Factor (IGF)-1 Signaling Pathway PFKFB3 Control of Cancer Growth by Responding to Circadian Clock Outputs Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism PFK15, a Small Molecule Inhibitor of PFKFB3, Induces Cell Cycle Arrest, Apoptosis and Inhibits Invasion in Gastric Cancer Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?Tumor bioenergetics: an emerging avenue for cancer metabolism targeted therapy Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth Bioenergetic mechanisms in astrocytes may contribute to amyloid plaque deposition and toxicity.Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor.Akt inhibition attenuates rasfonin-induced autophagy and apoptosis through the glycolytic pathway in renal cancer cells.Identification of Alternative Splicing and Fusion Transcripts in Non-Small Cell Lung Cancer by RNA Sequencing Clinical development of cancer therapeutics that target metabolism.Type 2 Diabetes Dysregulates Glucose Metabolism in Cardiac Progenitor Cells Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma Cancer cell metabolism and the modulating effects of nitric oxide.Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3).Stress eating and tuning out: cancer cells re-wire metabolism to counter stress.The wonders of 2-deoxy-D-glucose.Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression.PFKFB3 was overexpressed in gastric cancer patients and promoted the proliferation and migration of gastric cancer cells.The Role of Glucose and Lipid Metabolism in Growth and Survival of Cancer Cells.Immunometabolism in early and late stages of rheumatoid arthritis.Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.Metabolic reprogramming of alloantigen-activated T cells after hematopoietic cell transplantation Mechanical Activation of Hypoxia-Inducible Factor 1α Drives Endothelial Dysfunction at Atheroprone Sites.PFKFB3-Driven Macrophage Glycolytic Metabolism Is a Crucial Component of Innate Antiviral Defense.HIF-1α and PFKFB3 Mediate a Tight Relationship Between Proinflammatory Activation and Anerobic Metabolism in Atherosclerotic Macrophages.

P2860

Q26740187-4F81887D-4ED8-4DAA-8757-B0D939DF0C61 Q26745461-CCDE5D31-6467-4284-A1E2-5C20F0CC84E0 Q26784630-E0D5B589-37D9-4066-BEE7-8569D7F279F7 Q26795759-B81C90E1-2812-4AFD-BAD6-0491F7355F6B Q26798253-B0C81881-7140-4CF0-8073-3A09B5447D1A Q26827810-01CEE242-62E6-4C4F-AE1C-D4502208C800 Q27005930-DC8ECF22-8486-4F1A-8914-EE94BDC2CFBB Q27014979-24D3C50E-1157-4CB1-B968-7452184B5190 Q27693375-3F73B292-AAB1-45D7-B532-B04A14AA99EB Q28080316-22109AAF-73DB-45A4-841F-2AEDE3177E99 Q28080748-541925C6-C545-4A9D-B15C-8A9E400073D0 Q28235964-F91E9B4A-EC0D-479C-96FB-D5AE45F2A4F7 Q28244084-561F442F-46D2-4C48-9B94-4B9E5500F3FD Q28267012-E7ACEFFD-6611-41E8-B255-ADA6D06DDA8C Q28274910-4B687F64-79D8-4051-BC78-83FE262C151E Q28306357-EB3E21CB-BEF5-4152-867B-92E428668F5E Q28554349-3C6ECAF0-B83A-461E-9F4E-5F98D9AB24FE Q33917658-C521844D-1599-4FB2-B693-4EB5AD420210 Q34179999-B3FE953A-CCB4-46A2-BF70-9D763D644DC3 Q34334355-3CA6372E-6EB7-462A-8DC1-40F624F095A2 Q35608051-AB5AEC3C-3160-4B11-8E6D-A559E7272AB6 Q36228491-19BB328E-A619-4740-A016-A91A57B6CA28 Q36485132-798A50B3-4E4E-4E61-B096-EB06F8253C63 Q36772451-7991C628-FCBD-4956-9611-649A651D389E Q36988292-D5A50AE1-83BE-4E87-A55B-BE6C865EDA0D Q37034410-BC1BA28A-0CA5-4DCE-BBB0-9D718871DD25 Q37569380-1B55A321-F6D9-4543-86A7-E1CB7C458BAF Q37611425-16457440-8DEA-48A0-B99C-379CA3E3FA5C Q37691651-48C4F874-1954-49FB-BFD6-21B76D9D6BA2 Q38149940-B76DCA0C-1BD7-4CED-84FC-8ADECC86713F Q38191881-4891642C-DF72-4850-BDF5-7B614CA37EF1 Q38616121-EB640607-CF63-499D-AEF8-E65ABB90E999 Q38725920-269C7395-7D3D-4422-BF7F-5AD721D21B0B Q38936241-09652554-1F4D-4606-A0CE-A33574DFF7F7 Q39209693-5224DB6C-DD0E-4651-84DC-8307C147B663 Q39405012-2C7443CF-A214-4075-8F03-EC6D706E37A9 Q39617623-E278BCA1-4393-442A-89B6-434178855B2B Q40061820-6AF970D2-4DBB-445E-BB06-64412E994AD2 Q40561376-516331ED-0B61-4D6A-AA68-6AA49BB318CE Q40980593-3126C223-4B22-4978-A203-11A1DA99B278

P2860

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer

http://www.wikidata.org/entity/Q28290629

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer

@ast

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer

@en

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer

@nl

type

label

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer

@ast

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer

@en

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer

@nl

prefLabel

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer

@ast

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer

@en

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer

@nl

P1433

Q28290629-B5EE44B5-BB96-4FBC-9B2B-5DC8B1A95179

P1476

Q28290629-42BE1A66-636B-4476-8D6F-6C8A283765F0

P2093

Q28290629-47FE7C94-AAEE-4C12-B071-D48C02D6CC69

Q28290629-55170458-A456-4135-B2CD-6579C02CA88F

Q28290629-8688507D-5A5C-4E2D-9671-FD9D371999C2

Q28290629-A2670D0C-F6DA-40CE-AB57-22CDA18B3913

Q28290629-AD22D634-CF48-4F22-A09E-B39A04C92D5E

Q28290629-AFBAE0AB-3432-4857-A10B-FE6794461DA4

Q28290629-C692D8EF-F23A-4D69-9341-9D92575AAF79

Q28290629-D98382E4-2E29-4641-873C-E695F2809BE1

Q28290629-DF9EA833-1D0D-4106-B01F-FFEA14321FE0

Q28290629-E84B9A8C-DF06-4361-831C-FD166C186B44

P2860

Q28290629-0C277526-A33E-4AE9-BB3F-24EC95F09172

Q28290629-12E1D2C3-1DE7-44F7-9C6E-6602FC6CE2C0

Q28290629-1797C358-00DA-42B8-ADA0-82803713C946

Q28290629-2564FF08-9F81-4387-986B-85FF3F89A851

Q28290629-26043A3D-3969-49C3-87C2-4107CCA8E7A7

Q28290629-5D5326C6-C654-4A03-8C0B-CD2F54925B5A

Q28290629-6AEF3E7D-4273-400C-A781-FFD4DA2945C6

Q28290629-739D4438-C275-4E62-8502-2C983C762009

Q28290629-8590352E-5919-433C-B907-FC1C4762CC69

Q28290629-8B2958CA-D951-4D03-85BD-4D35AE798674

P304

Q28290629-928AB282-A9B2-4348-9010-E29FC077658E

P31

Q28290629-21D2DA0C-1A95-4AAC-9AC9-E344C1F8EBB3

P3181

Q28290629-F535AAAA-D76A-4850-A3EA-AECA4A454BD6

P356

Q28290629-7B948FB2-6690-4700-8DE1-A2ED55877990

P407

Q28290629-28F78925-0A08-4960-8021-3A2E9E85B2B7

P433

Q28290629-242101AF-087A-4171-82D8-A1D36C94F0B4

P478

Q28290629-2515A4DD-AF97-404A-98AC-6AFE5A0BFDCA

P577

Q28290629-455587FC-7F07-409A-887A-E6E9BA9962B2

P5875

Q28290629-8323BEC6-95DF-4BB7-9420-D35124CE61CB

P698

Q28290629-C90CD88B-5A7D-485D-AFCE-E4B2CABC1F82

P932

Q28290629-C96ECDE1-D774-4F6D-9E09-649A9F9171CB

P3181

P356

1535-7163.MCT-13-0097

P1433

Molecular Cancer Therapeutics

P1476

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer

@en

P2093

Alden C Klarer

http://www.w3.org/2001/XMLSchema#string

Amy L Clem

http://www.w3.org/2001/XMLSchema#string

Brian F Clem

http://www.w3.org/2001/XMLSchema#string

Daniel A Kerr

http://www.w3.org/2001/XMLSchema#string

Donald M Miller

http://www.w3.org/2001/XMLSchema#string

Gilles Tapolsky

http://www.w3.org/2001/XMLSchema#string

Jason Chesney

http://www.w3.org/2001/XMLSchema#string

John O Trent

http://www.w3.org/2001/XMLSchema#string

Julie O'Neal

http://www.w3.org/2001/XMLSchema#string

Rebecca Redman

http://www.w3.org/2001/XMLSchema#string

P2860

The kinase activity of human brain 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase is regulated via inhibition by phosphoenolpyruvate

High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers

6-Phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia

The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2-kinase.

The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation

Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation.

An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect.

Control of liver 6-phosphofructokinase by fructose 2,6-bisphosphate and other effectors

The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity

Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.

P304

1461-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

100436

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1535-7163.MCT-13-0097

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236837869

http://www.w3.org/2001/XMLSchema#string

P698

23674815

http://www.w3.org/2001/XMLSchema#string

P932

3742633

http://www.w3.org/2001/XMLSchema#string